+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tuberculosis Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 283 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227810
The global market for Tuberculosis Therapeutics is estimated at US$886.2 Million in 2023 and is projected to reach US$1.1 Billion by 2030, growing at a CAGR of 2.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the tuberculosis therapeutics market is driven by several factors. Advances in molecular biology and genomics have facilitated the identification of new drug targets, leading to the development of more effective and less toxic TB drugs. Increased funding from governments and international organizations has spurred research and development activities. The rising prevalence of drug-resistant TB strains has created an urgent need for new treatments, thereby driving market demand. Additionally, public health initiatives aimed at TB elimination, such as the World Health Organization`s End TB Strategy, have bolstered the focus on developing new therapeutics. Technological innovations in drug delivery systems, such as nanotechnology-based formulations, have improved drug bioavailability and patient outcomes. The growing awareness and proactive healthcare-seeking behavior among populations in high-burden regions are also contributing to market expansion. Lastly, the integration of digital health technologies to enhance treatment adherence and the implementation of robust surveillance systems to monitor disease trends are pivotal factors fueling market growth.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Active TB Therapeutics segment, which is expected to reach US$654.3 Million by 2030 with a CAGR of a 2.9%. The Latent TB Therapeutics segment is also set to grow at 2.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $240.5 Million in 2023, and China, forecasted to grow at an impressive 4.7% CAGR to reach $208.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Tuberculosis Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Tuberculosis Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Tuberculosis Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 37 Featured):

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Tuberculosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Drug-Resistant TB Strains Drives Demand for New Treatments
  • Public Health Initiatives Strengthen Business Case for Novel Therapeutics
  • Increased Funding and Government Initiatives Expand Addressable Market Opportunity
  • Advances in Molecular Biology and Genomics Propel Growth
  • Technological Innovations in Drug Delivery Systems Accelerate Demand for Advanced Therapies
  • Growing Awareness and Proactive Healthcare-Seeking Behavior Spur Market Growth
  • Improved Diagnostic Technologies Propel Growth in Early Detection and Treatment
  • Development of Shorter Treatment Regimens Generates Demand for New Drug Combinations
  • Vaccine Development and Research Throws the Spotlight on Preventive Measures
  • Implementation of Robust Surveillance Systems Drives Demand for Data-Driven Solutions
  • Nanotechnology-Based Formulations Expand Addressable Market Opportunity
  • Economic Burden of TB Creates Opportunities for Cost-Effective Therapeutics
  • Focus on TB Eradication Worldwide Generates Demand for Comprehensive Solutions
  • Social and Behavioral Interventions Enhance Patient Engagement and Drive Adoption
  • Personalized Medicine and Tailored Therapies Sustain Growth by Improving Efficacy and Outcomes
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Tuberculosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Active TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Latent TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for First-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Second-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 18: USA Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: USA 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
JAPAN
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
CHINA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: China Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: China 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
EUROPE
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Europe 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
FRANCE
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: France Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: France 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: France Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: France 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
GERMANY
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: Germany 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Germany 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Italy 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Italy 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: UK Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: UK 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: UK Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: UK 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
SPAIN
  • Table 74: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: Spain Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: Spain 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 77: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: Spain Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: Spain 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
RUSSIA
  • Table 80: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Russia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Russia 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 83: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Russia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Russia 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Rest of Europe 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
AUSTRALIA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

Table Information